Kornimate/medical-research-clean huggingface dataset:
u shaped toothbrush in removing plaque in children

Conditions: Dental Plaque

Summary: the aim of this study is to evaluate the effectiveness of a u-shaped toothbrush in removing plaque in preschool children which can be a simple, acceptable, and effective way to remove plaque in children in order to improve their oral health in the absence of parental supervision. children accepted in the study will be randomly divided into two groups: the traditional toothbrush group and the u-shaped toothbrush group, all children aged four to five years will have their plaque assessed with the turesky modified quigley hein index (tmqh)

this study will evaluate the effectiveness u-shaped toothbrush in removing plaque and improving oral health. children were randomly assigned to one of the following groups: group a: children in this group will use a traditional brush first to clean their teeth then will use u shaped brush later. group b: children in this group will use a u-shaped brush first to clean their teeth then will use a traditional brush later the plaque will be assessed by a blinded evaluator using the turesky modified quigley hein index (tmqh) in both groups at 4 different times(t0): before brush (t1): after brush (t2): a week after use (t3): a month of use the toothbrush will be changed after one month of use.

Eligibility criteria:
inclusion criteria: medically free children. complete temporary occlusion (no missing temporary teeth). the parents' approval for the child to enter the study. exclusion criteria: children with limited ability to communicate. children with motor disabilities.

Keywords: u shaped toothbrush traditional toothbrush plaque removal oral hygiene pre-schooled children
female patients with signs of urge and stress urinary incontinence study of propiverine hydrochloride

Conditions: Urinary Incontinence

Summary: this study is to evaluate the efficacy and safety that the occurrence of incontinence is significantly decrease using the propiverine hydrochloride for 200 female patients with mixed (stress and urge) urinary incontinence in one week during a twelve-week treatment period.


Eligibility criteria:
inclusion criteria: 1. female patients with mixed urinary incontinence (mui) 2. patients having symptoms of urinary incontinence for at least 3 months 3. patients having at least one episode of urge urinary incontinence per week and 4 episodes of stress urinary incontinence per week in a bladder diary. 4. 20 years old or older 5. patients who meet all the following criteria in iciq-sf (1) "2-3 times or more in one week" was selected at q1. (2) "small or more" was selected at q2. (3) "leak at the time of cough or sneeze" or "leak at the time of exercise" was selected at q4. 6. less than 100ml of residual urine volume 7. written informed consent. exclusion criteria: 1. patients with organ disease such as bladder stones, bladder tumors and urethral stricture in the lower urinary tract 2. patients with bacterial infections (i.e. bacterial cystitis) or nonbacterial infections (i.e. interstitial cystitis) 3. patients with advanced lower urinary tract obstruction or urinary retention 4. patients without urinary sensation 5. patients with overflow incontinence 6. patients with history or complications of pelvic organ prolapse 7. patients with pyloric, duodenal or intestinal obstruction 8. patients with gastric or intestinal atony 9. patients with angle-closure glaucoma 10. patients with myasthenia gravis 11. patients with severe heart disease 12. patients with severe constipation 13. patients with dementia who are not able to complete the questionnaires 14. patients with history of allergic reaction to propiverine hydrochloride or other similar medicine 15. patients with history of surgery that affect urination such as trans-obturator tape（tot）or tension-free vaginal tape（tvt） 16. women who are pregnant, lactating, potentially pregnant or willing to get pregnant 17. patients with previous surgery of the abdomen and pelvis or radiation within 6 months 18. patients who started pelvic floor muscle exercise within 3 months 19. patients who took propiverine hydrochloride or other similar medicine within 2 weeks before entry 20. judged as being unsuitable for the trial by physician.

Keywords: female mixed urinary incontinence
docetaxel in treating women with ovarian epithelial or primary peritoneal cancer

Conditions: Ovarian Cancer; Peritoneal Cavity Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of docetaxel in treating women who have ovarian epithelial cancer or primary peritoneal cancer that has not responded to previous treatment.

objectives: * determine the activity of docetaxel in women with platinum resistant, refractory ovarian epithelial or primary peritoneal serous cancer. outline: patients receive docetaxel iv over 30 minutes on days 1, 8, and 15. courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. patients achieving complete response (cr) receive a minimum of 6 courses of therapy, including 2 courses beyond cr. projected accrual: a total of 20-30 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * histologically confirmed ovarian epithelial or primary peritoneal serous cancer that is resistant to platinum therapy * platinum resistance as defined by one of the following: * relapse within 6 months of platinum based chemotherapy * residual disease after completion of platinum based chemotherapy * disease progression while receiving platinum based chemotherapy * marker only relapse (ca-125 elevation) and measurable disease * bidimensionally measurable disease on exam or ct scan patient characteristics: age: * 18 and over sex: * female performance status: * ecog 0-2 life expectancy: * greater than 2 months hematopoietic: * wbc at least 3,000/mm3 * absolute neutrophil count at least 1,500/mm3 * platelet count at least 100,000/mm3 hepatic: * bilirubin no greater than upper limit of normal (uln) * sgpt or sgot no greater than 1.5 times uln * alkaline phosphatase no greater than 2.5 times uln renal: * creatinine no greater than 1.5 mg/dl cardiovascular: * acceptable cardiac exam * no active cardiac ischemia pulmonary: * acceptable pulmonary exam * no active pulmonary infection or compromise other: * not pregnant or nursing * no severe peripheral neuropathy (grade 2 or greater) * no other significant psychiatric or medical conditions that would interfere with compliance * no other malignancies within the past 3 years, except: * limited basal or squamous cell skin cancer * carcinoma in situ of the cervix prior concurrent therapy: biologic therapy: * no prior cytokine therapy chemotherapy: * see disease characteristics * at least 3 weeks since prior chemotherapy for ovarian epithelial or peritoneal serous cancer * prior paclitaxel allowed * no prior docetaxel * at least 3 years since prior chemotherapy for other disease endocrine therapy: * not specified radiotherapy: * no prior pelvic radiotherapy surgery: * not specified

Keywords: recurrent ovarian epithelial cancer peritoneal cavity cancer
arthroscopic clinical study of double bundle anatomical reconstruction of medial patellofemoral ligament

Conditions: Recurrent Patellar Dislocation

Summary: objective: to study the clinical effect of double-beam anatomical reconstruction of medial patellofemoral ligament under arthroscopy. methods: double-beam anatomical reconstruction of medial patellofemoral ligament was performed under arthroscopy in patients admitted to our hospital for treatment of recurrent patellar dislocation. carry out preoperative and postoperative evaluations, and conduct preoperative and postoperative comparative studies to clarify the clinical effect of the procedure. expected results: arthroscopic double-beam anatomical reconstruction of the medial patellofemoral ligament can effectively restore the stability of the patella and the motor function of the knee joint. expected conclusion: arthroscopic double-beam anatomical reconstruction of the medial patellofemoral ligament is an effective minimally invasive technique. keywords: knee joint; medial patellofemoral ligament; double-beam anatomical reconstruction; arthroscopy


Eligibility criteria:
inclusion criteria: * 17\<age\<60 years * recurrent patellar dislocation or instability exclusion criteria: - bone spurs or bone protrusions on the d-type of the femoral pulley or proximal of the pulley.

Keywords: arthroscopy medial patellofemoral ligament
patient convenience study (re-sonance)

Conditions: Atrial Fibrillation; Stroke

Summary: the aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using pradaxa to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its approved indication in the approved dosages of 110 milligrams or 150 milligrams twice daily) in comparison to standard care using vitamin k antagonist (vka).


Eligibility criteria:
inclusion criteria: cohort a: 1. a. written informed consent prior to participation 2. a. female and male patients \>= 18 years of age with a diagnosis of non-valvular atrial fibrillation. 3. a. at least 3 months of continuous vka treatment for stroke prevention prior to baseline assessment. 4. a. patients switched to pradaxa according summary of product characteristics and physician's discretion. or cohort b: 1. b. written informed consent prior to participation. 2. b. female and male patients \>= 18 years of age newly diagnosed with non-valvular atrial fibrillation and no previous treatment for stroke prevention (no use of any oral anticoagulant (oac) within one year prior to enrolment). 3. b. stroke prevention treatment initiated with pradaxa or vka according to summary of product characteristics and physician's discretion. exclusion criteria: 1. contraindication to the use of pradaxa or vka as described in the summary of product characteristics (smpc). 2. patients receiving pradaxa or vka for any other condition than stroke prevention in atrial fibrillation. 3. current participation in any clinical trial of a drug or device. 4. current participation in an european registry on the use of oral anticoagulation in af.
study of afflovest in at-risk respiratory patients during covid-19 pandemic

Conditions: Chronic Obstructive Pulmonary Disease; Chronic Cough; Covid19

Summary: the purpose of the study is to investigate the addition of high frequency chest wall oscillation (hfcwo) therapy to the prescribed care regimen to support the diaphragm during airway clearance among post-covid patients with copd and chronic productive cough as a way to limit the advancement of pulmonary symptoms and need for critical services during recovery from covid-19.

thirty study participants in new york city who meet inclusion criteria will be recruited from mount sinai's covid-19 post-recovery center of excellence and respiratory institute. fifteen subjects (determined by the last digit of their medical record number) will receive a hfcwo device (afflovest), digital thermometer, pulse oximeter, and spirometer at their home. participants will be trained remotely to use the afflovest and spirometer. in addition all subjects will be asked to complete a series of online mental health and respiratory symptom assessments via redcap. a 15 patient control group meeting inclusion criteria will be recruited from the mount sinai covid-19 post-recovery center of excellence and respiratory institute using the same screening process. this group will not receive the hfcwo intervention but will receive a digital thermometer, pulse oximeter, and spirometer at their home (with training via telehealth), asked to complete all redcap and respiratory symptom assessments. consent for both groups will be obtained by a mount sinai clinician-researcher. study duration approximately 30 days plus 60 and 90-day check in objectives to investigate the addition of hfcwo therapy to the prescribed care regimen to support the diaphragm during airway clearance among post-covid patients with copd and chronic productive cough as a way to limit the advancement of pulmonary symptoms and need for critical services during recovery from covid-19.

Eligibility criteria:
inclusion criteria: * adult males and females ≥18 years * existing diagnosis of copd for \>6 months * chronic productive cough * radiographic evidence of flattening of the diaphragm * prior covid-19 diagnosis * clinically followed by mount sinai covid-19 post recovery and respiratory institute. * ability to provide informed consent * ability to read and fill out survey questionnaires via redcap (surveys will be available in english and spanish) * access to a home computer, tablet, or smartphone exclusion criteria: * presenting with hypoxia (02 sat \<90%) * acute covid-19 infection * home oxygen dependent * established diagnosis of cystic fibrosis * history of osteoporosis or rib fracture * active hemoptysis * pneumothorax

Keywords: pulmonary disease airway clearance therapy high frequency chest wall oscillation
the emotional and functional benefits of poly-l-lactic acid

Conditions: Facial Volume Loss

Summary: this study will evaluates the emotional and functional benefits of poly-l-lactic acid (sculptra™), a cosmetic product used to fill defects of the skin. all participants will receive sculptra™.

facial volume loss can result in emotional distress and functional impairment in some affected individuals. poly-l-lactic acid (sculptra™) stimulates collagen production in the skin thereby replenishing some of the collagen lost to natural aging and ultraviolet damage. this study will assess the emotional and functional benefits of poly-l-lactic acid treated subject's through self report measurement tools.

Eligibility criteria:
inclusion criteria: 1. subject must be an outpatient, male or female subjects of any race, 35 years of age or older. 2. subject must have any degree of facial volume loss. 3. subjects of all fitzpatrick skin types are eligible. 4. subject must be able to follow study instructions and likely to complete all required visits, as assessed by the investigator. 5. subject must sign an irb-approved informed consent form, photographic release form, and the authorization for use and release of health and research study information (hipaa) form prior to any study-related procedures being performed. exclusion criteria: 1. any of the previous facial treatments: c. any facial filler in the past 2 years d. prior injection of permanent facial implant 2. have any skin pathology or condition that could interfere with the evaluation of the face. 3. be unable to communicate or cooperate with the investigator due to a language barrier (non-english speaking), poor mental development, or impaired cerebral function. 4. have evidence of alcohol or drug abuse (investigator opinion), or history of poor cooperation, non-compliance with medical treatment, or unreliability. 5. have used an investigational device, biologic or drug in the past 30 days, or be currently participating in an experimental drug, biologic or device trial. 6. have a condition or be in a situation that, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study. 7. be an employee (or a relative of an employee) of the investigator, sponsor or representative of the sponsor.
the effect of virtual reality treadmill-based gait training on gait and balance ability in chronic stroke patients

Conditions: Stroke; Hemiplegia

Summary: walking independence is one of the most important goals for stroke patients and a major factor influencing their return to society after the onset of stroke. stroke patients experience walking difficulties due to hemiplegia and have an increased risk of falls due to impaired balance ability. recent studies have shown that treadmill-based walking training incorporating virtual reality can help improve walking and balance functions in actual stroke patients. however, there are few randomized clinical trials with control groups, highlighting the need for further research to ensure the reliability of clinical effects. therefore, this study aims to investigate the impact of treadmill-based training incorporating virtual reality on walking and balance functions. the training equipment to be used is the c-mill vr+ device, which enables walking training and assessment, balance training and assessment, and obstacle training using a front screen and treadmill videos. the investigators intend to thoroughly examine the walking ability and balance ability of the subjects obtained through this equipment, along with various evaluation tools.


Eligibility criteria:
* inclusion criteria: 1. adult patients aged 19 years or older. 2. confirmed diagnosis of stroke by a neurologist or neurosurgeon through radiological methods such as ct or mri. 3. chronic hemiplegic stroke patients, six months post-stroke onset. 4. patients with a functional ambulatory category score of 3 or higher. 5. patients with a mini-mental state examination (mmse) score of 10 or higher, who understand the study, are willing to participate voluntarily, and have given consent to participate. * exclusion criteria: 1. acute/subacute stroke patients within six months of stroke symptom onset. 2. patients with quadriplegia. 3. patients with ataxia. 4. patients with severe joint contracture of the lower limbs that makes wearing orthotics difficult. 5. patients with neurological, musculoskeletal, or cardiopulmonary diseases that affect walking. 6. any other cases deemed inappropriate for participation by the researcher.
an observational study to evaluate long-term retention rate of topiramate in participants with epilepsy

Conditions: Epilepsy

Summary: the purpose of this study is to evaluate the long-term retention rate of topiramate in participants with epilepsy (seizure disorder).

this is an open-label (a medical research study in which participants and researchers are told which treatments the participants are receiving, "unblinded"), single-arm, prospective (study following participants forward in time), observational (a clinical study in which participants identified as belonging to study groups are assessed for biomedical or health outcomes) and multi-center (when more than one hospital or medical school team work on a medical research study) study of topiramte in participants with epilesy. the study population will be all the epilepsy participants visiting outpatient study center over a period of two months. topiramate will be administered as per investigator's discretion for 52 weeks. participants will visit the trial site for evaluation of endpoint at baseline, week 12, week 26, and week 52. efficacy will primarily be evaluated by percentage of participants which will be retained to topiramate treatment uptil week 52. participants' safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * participants with all type of epilepsy * participants with more than 2 episodes of seizure during last 1 year * participants who can comply with the visit schedule and are willing and able to complete evaluation procedures specified in the protocol during the treatment period * female participants with child bearing potential and who use proper contraceptive methods during the study period exclusion criteria: * participants who have known hypersensitivity reaction or allergy to the study drug * participants who have taken topiramate within the three months of study start * participants who are determined not to be suitable for the clinical study participation by an investigator's discretion * pregnant and nursing female participants

Keywords: epilepsy topiramate topmax
institut paoli-calmettes pancreatic neoplasms database

Conditions: Pancreatic Neoplasms

Summary: database of institut paoli calmettes diagnosed with pancreatic neoplasms


Eligibility criteria:
inclusion criteria: * patient with a diagnosis of pancreatic neoplasm exclusion criteria: * patient with a diagnosis of cholangiocarcinoma
analysis of predictive factors for urinary leakage after partial nephrectomy for renal hilum tumors

Conditions: Partial Nephrectomy; Renal Hilum Tumors; Urinary Leakage

Summary: in this study, we plan to explore the risk factors closely related to the occurrence of urinary leakage after partial nephrectomy for renal hilum tumors through retrospective analysis of multicenter clinical data, thereby providing clinical guidance value for the prevention of postoperative urinary leakage.


Eligibility criteria:
inclusion criteria: * ct or mri angiography indicates a renal hilum tumor, and the patient has undergone partial nephrectomy; * the eastern cooperative oncology group (ecog) performance status score is between 0 and 1, and the age is between 18 and 75 years old; * the clinicopathological data are complete; * there is no infection, autoimmune disease, hematological disease, or other malignancies. exclusion criteria: * the patient has surgical contraindications; * there are congenital malformations of the urinary system, obstructive nephropathy, or other diseases that seriously affect the function of the urinary system before surgery; * the patient has received relevant treatments that may affect the results of this study, such as radiotherapy in the kidney area, a history of kidney surgery, etc.; * there are tumors in both kidneys.

Keywords: urinary leakage partial nephrectomy renal hilum tumors
study in patients with kidney cancer treated with sutent

Conditions: Advanced or Metastatic Renal Cell Carcinoma; Renal Cancer

Summary: objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.

consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

Eligibility criteria:
inclusion criteria: * consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy exclusion criteria: * hypersensitivity to sunitinib malate or to any of the excipients * any other contraindication to the use of sunitinib malate (based on decision of the treating physician).

Keywords: renal cell carcinoma sunitinib malate